← All Biocryst Pharmaceuticals INC filings

Biocryst Pharmaceuticals INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Reports Q3 Profit, ORLADEYO Growth, Astria Merger
BioCryst Pharmaceuticals achieved net income and positive operating cash flow in Q3 2025, driven by strong ORLADEYO sales, and announced a strategic merger with Astria Therapeutics.
NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Achieves Profitability, Boosts ORLADEYO Sales
BioCryst Pharmaceuticals reports significant revenue growth and net income for the first half of 2025, driven by strong ORLADEYO sales and strategic debt reduction.
NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Reports Q1 2025 Results: Revenue Surges on Strong ORLADEYO Demand
BioCryst reports a strong first quarter in 2025, driven by increased ORLADEYO sales and progress in its clinical development programs.
NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Pharmaceuticals Reports Q3 2024 Results: Revenue Growth Driven by ORLADEYO Sales
BioCryst Pharmaceuticals saw a significant increase in revenue in Q3 2024, primarily driven by sales of its hereditary angioedema drug, ORLADEYO, despite ongoing losses.
NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Pharmaceuticals Reports Q2 2024 Results: Revenue Growth Offset by Losses
BioCryst Pharmaceuticals saw a revenue increase in Q2 2024, driven by ORLADEYO sales, but still reported a net loss due to high operating expenses and interest costs.
NASDAQ
BCRX
Biocryst Pharmaceuticals INC
10-Q: BioCryst Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Driven by Orladeyo Sales
BioCryst Pharmaceuticals saw a revenue increase in the first quarter of 2024, primarily driven by sales of Orladeyo, despite ongoing operating losses.